• First pneumococcal conjugate vaccine that protects against 20 serotypes responsible for the majority of invasive pneumococcal disease and pneumonia[1],[2],[3],[4],[5],[6],[7]. In Singapore, pneumonia is the third leading cause of death[8] and fourth most common cause of hospitalisations[9]

• Offers the broadest serotype coverage of any pneumococcal conjugate vaccine currently available, building on Pfizer's more than 20-year legacy and innovation in developing pneumococcal conjugate vaccines

• Approval of APEXXNAR in Singapore, the first in Southeast Asia, aligns with Singapore's Healthier SG Strategy to place a sustained focus on preventive care in achieving overall healthier living

SINGAPORE - Media OutReach - 18 March 2023 - Pfizer announced today that the Singapore Health Sciences Authority (HSA) has approved its 20-valent pneumococcal conjugate vaccine (PCV20) that protects against invasive pneumococcal disease and pneumonia caused by 20 Streptococcus pneumoniae (pneumococcus) serotypes. Marketed under the brand name APEXXNAR, this vaccine is approved for active immunisation for individuals aged 18 years and older, advancing the company's ongoing commitment to help prevent certain potentially-serious infectious respiratory diseases.

The approval of APEXXNAR in Singapore, being the first in Southeast Asia, underscores Pfizer's 20 years of growing legacy and experience in developing and supplying innovative pneumococcal conjugate vaccines that have had a pivotal impact on the global disease burden. This approval also supports Singapore's Healthier SG initiative that f...